Arvinas, Inc. (NASDAQ:ARVN) Receives $14.17 Consensus Target Price from Analysts

Shares of Arvinas, Inc. (NASDAQ:ARVN) have been assigned an average rating of “Hold” from the eleven research firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $14.1667.

Several brokerages recently issued reports on ARVN. Evercore set a $14.00 price target on Arvinas in a report on Monday, August 10th. Wall Street Zen upgraded Arvinas from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. BTIG Research reaffirmed a “buy” rating and set a $18.00 price objective on shares of Arvinas in a report on Tuesday, August 4th. Wedbush lifted their price objective on shares of Arvinas from $11.00 to $12.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Finally, Stephens reiterated an “overweight” rating and issued a $18.00 target price on shares of Arvinas in a research note on Wednesday, June 3rd.

Insider Transactions at Arvinas

In other Arvinas news, CFO Andrew Saik sold 5,696 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $8.16, for a total value of $46,479.36. Following the completion of the sale, the chief financial officer owned 187,432 shares in the company, valued at approximately $1,529,445.12. This trade represents a 2.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 7.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ARVN. Integrated Wealth Concepts LLC bought a new stake in shares of Arvinas in the second quarter valued at about $48,000. Quantbot Technologies LP acquired a new position in Arvinas in the 2nd quarter valued at approximately $85,000. Corient Private Wealth LP acquired a new position in Arvinas in the 2nd quarter valued at approximately $95,000. Pale Fire Capital SE bought a new stake in shares of Arvinas in the 2nd quarter worth approximately $99,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Arvinas in the 2nd quarter worth approximately $112,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Stock Performance

ARVN stock opened at $8.29 on Friday. The company has a market capitalization of $534.87 million, a P/E ratio of 82.91 and a beta of 1.75. Arvinas has a 52-week low of $6.97 and a 52-week high of $14.51. The business has a 50-day simple moving average of $8.72 and a two-hundred day simple moving average of $9.45.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $2.95. Arvinas had a return on equity of 1.91% and a net margin of 2.94%.The firm had revenue of $249.70 million during the quarter, compared to analyst estimates of $60.71 million. During the same period in the previous year, the company posted ($0.84) EPS. The company’s revenue for the quarter was up 1014.7% on a year-over-year basis. As a group, sell-side analysts forecast that Arvinas will post 0.05 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company’s approach, known as targeted protein degradation, uses proprietary PROTAC technology to direct specific proteins to the cell’s natural disposal machinery. Arvinas applies this platform primarily to cancer and other serious diseases in which abnormal or unwanted proteins contribute to disease progression.

Arvinas’ pipeline has included vepdegestrant, formerly known as ARV-471, an investigational oral estrogen receptor degrader being developed for patients with estrogen receptor-positive, HER2-negative breast cancer.